Energenesis Biomedical Co

Energenesis Biomedical Co Current Liabilities

The Current Liabilities of Energenesis Biomedical Co (6657.TW) as of Oct 31, 2026 is 43.42 M TWD. In the previous year, Current Liabilities was 76.59 M TWD — a change of -43.31% (lower).

Current Liabilities

43.42 MTWD

YoY

-43.31%

Last updated:

Current Liabilities of Energenesis Biomedical Co is 2025 43.42 M TWD. Current Liabilities of Energenesis Biomedical Co was 2024 76.59 M TWD. It decreases by -43.31% lower compared to the previous year.

The Energenesis Biomedical Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
12.30 M TWD
Jan 1, 2019
30.85 M TWD
Jan 1, 2020
39.99 M TWD
Jan 1, 2021
44.94 M TWD
Jan 1, 2022
59.15 M TWD
Jan 1, 2023
38.85 M TWD
Jan 1, 2024
76.59 M TWD
Jan 1, 2025
43.42 M TWD
The Energenesis Biomedical Co Current Liabilities history
YEARCurrent LiabilitiesYoY
43.42 MTWD-43.31%
76.59 MTWD+97.15%
38.85 MTWD-34.32%
59.15 MTWD+31.61%
44.94 MTWD+12.39%
39.99 MTWD+29.62%
30.85 MTWD+150.82%
12.30 MTWD-24.54%
16.30 MTWD+91.76%
8.50 MTWD+183.33%
3.00 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Energenesis Biomedical Co Stock analysis

What does Energenesis Biomedical Co do? Energenesis Biomedical Co., Ltd. develops new drugs, focusing on experimental service analysis and reagent sales as its main products. The company's primary new drugs include ENERGI-F703 for diabetic foot ulcers, ENERGI-F701 for abnormal alopecia, ENERGI-F711 for burns, and ENERGI-F706 for cachexia. These products target medical professionals and healthcare institutions seeking innovative treatments for specific conditions. The firm generates revenue through the sale of experimental services and reagents, as well as the commercialization of its drug pipeline. Energenesis Biomedical's product portfolio is centered around four key drug candidates, each addressing distinct medical needs. ENERGI-F703 addresses diabetic foot ulcers, a common complication in diabetes management, while ENERGI-F701 targets abnormal alopecia, a condition affecting hair growth. ENERGI-F711 is designed for burn treatment, and ENERGI-F706 focuses on cachexia, a wasting syndrome often associated with chronic diseases. These drugs are developed for direct sales to healthcare providers and institutions. The company's revenue streams are derived from two main areas: the sale of experimental service analysis and reagent products, alongside the future commercialization of its drug candidates. Healthcare institutions and medical professionals are the primary buyers of these products, seeking advanced solutions for diabetic foot ulcers, alopecia, burns, and cachexia. Energenesis Biomedical's business model relies on the successful development and market entry of its drug pipeline to generate sustained revenue. Energenesis Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Energenesis Biomedical Co stock

Current Liabilities of Energenesis Biomedical Co is 43.42 M TWD in 2025.

Current Liabilities of Energenesis Biomedical Co changed from 76.59 M TWD to 43.42 M TWD, representing a -43.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Energenesis Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Energenesis Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Energenesis Biomedical Co

All Key Metrics — Energenesis Biomedical Co